GlobalData on MSN1mon
Penumbra reveals positive data for algorithm-assisted thrombectomy techResource use and health outcomes with Penumbra’s tech were pitted against standard procedures such as anticoagulation, ...
Penumbra, Inc. (PEN): Innovating in Thrombectomy and Embolization with New FDA-Approved Technologies
Penumbra, Inc. (NYSE ... another solid double digit performance in stroke thrombectomy. As interest wanes in the Super Large Bore OE8 catheters as aspiration catheters, most of the companies ...
Oppenheimer predicts growth for Penumbra Inc in MT market. Analyst initiates coverage with Outperform rating and $275 target ...
Oppenheimer initiated coverage of Penumbra (PEN) with an Outperform rating and $275 price target Penumbra is a leader in the mechanical ...
The first option consisted of a reperfusion catheter that ... retrieval device and the Penumbra Stroke System®are US FDA-approved endovascular devices for thrombectomy in acute ischemic stroke ...
The positive outcomes observed in this study, in contrast to some negative previous investigations, may be further explained by shorter procedural time, use of newer thrombectomy catheters and ...
Penumbra, Inc. (NYSE ... reported compared to other methods like anticoagulation, catheter-directed thrombolysis, or mechanical thrombectomy devices. Dr. Parag J. Patel, an interventional ...
Penumbra, Inc. (PEN): Innovating in Thrombectomy and Embolization with New FDA-Approved Technologies
In this article, we are going to take a look at where Penumbra, Inc. (NYSE:PEN) stands against Well Fargo's other growth stocks. With the interest rate cycle kicking off in the US, stocks that are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback